Patents
US 11850225 B2: Baclofen formulations and methods of minimizing patient exposure to metabolite variations
- Granted
- 2023-12-26
- Filed
- 2022-07-11 application 17861844
- Type
- Utility · 19 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.
Source: PVGPATDIS, file of 2026-04-10 (ipg231226.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| AMNEAL PHARMACEUTICALS LLC 33 patents | US company or organization | Bound Brook Junction, NJ | AMNEAL PHARMACEUTICALS LLC Federal lobbying client EXACT high confidence: identical full name and state AMNEAL PHARMACEUTICALS, INC. SEC filer FUZZY low confidence: same name (legal endings aside), one of each nationally | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Leonard O'Mahony | Mullingar, IE | 12 | PVGPATDIS, file of 2026-04-10 | |
| Sharon Hamm | Gulf Pine, FL | 18 | PVGPATDIS, file of 2026-04-10 | |
| John Devane | Dublin, IE | 16 | PVGPATDIS, file of 2026-04-10 | |
| David Penake | Atlanta, GA | 21 | PVGPATDIS, file of 2026-04-10 | |
| Wolfgang Mohr | Freiburg (Elbe), DE | 7 | PVGPATDIS, file of 2026-04-10 | |
| Manuel Weinheimer | Neustadt an der Weinstraße, DE | 6 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K31/197 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2025-08-01 | Security interest Security interest Patent security agreement | AMNEAL PHARMACEUTICALS LLC signed 2025-08-01 IMPAX LABORATORIES, LLC signed 2025-08-01 GEMINI LABORATORIES, LLC signed 2025-08-01 | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT WILMINGTON, DE | 72312/127 | PASDL, file of 2026-10-25 |
| 2023-11-17 | Security interest Security interest Security interest | AMNEAL PHARMACEUTICALS LLC signed 2023-11-14 | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT CHICAGO, IL | 65602/692 | PASDL, file of 2026-10-15 |
| 2023-11-16 | Security interest Security interest Patent security agreement | AMNEAL PHARMACEUTICALS LLC signed 2023-11-14 | TRUIST BANK, AS ADMINISTRATIVE AGENT ATLANTA, GA | 65610/793 | PASDL, file of 2026-10-15 |
| 2023-03-23 | Assignment Assignment of assignor's interest | MOHR, WOLFGANG signed 2023-03-06 WEINHEIMER, MANUEL signed 2023-03-22 | AMNEAL PHARMACEUTICALS LLC BRIDGEWATER, NJ | 63078/131 | ECORSEXC, file of 2026-09-25 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.